Seminars in Diagnostic Pathology
Volume 26, Issue 3 , Pages 131-140 , August 2009

Cutaneous CD30 lymphoproliferative disorders and similar conditions: a clinical and pathologic prospective on a complex issue

  • Joan Guitart, MD

      Affiliations

    • Cutaneous Lymphoma Clinic and Dermatopathology Laboratory, Northwestern University, Feinberg Medical School, Chicago, Illinois
    • Corresponding Author InformationAddress for correspondence: Joan Guitart, MD, Department of Dermatology, Northwestern University, Feinberg Medical School, 676 North Saint Clair, Suite 1600, Chicago, IL 60611
    • ,
  • Christiane Querfeld, MD

      Affiliations

    • University of Chicago, Section of Dermatology, Chicago, Illinois

References 

  1. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354–371
  2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785
  3. Macauley WL. In defense of lymphomatoid papulosis. Arch Dermatol. 1971;104:434
  4. Heald P, Subtil A, Breneman D, Wilson LD. Persistent agmination of lymphomatoid papulosis: An equivalent of limited plaque mycosis fungoides type of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2007;57:1005–1011
  5. Scarisbrick JJ, Calonje E, Orchard G, et al. Pseudocarcinomatous change in lymphomatoid papulosis and primary cutaneous CD30+ lymphoma: A clinicopathologic and immunohistochemical study of 6 patients. J Am Acad Dermatol. 2001;44:239–247
  6. Pujol RM, Muret MP, Bergua P, et al. Oral involvement in lymphomatoid papulosis (Report of two cases and review of the literature). Dermatology. 2005;210:53–57
  7. Liu HL, Hoppe RT, Kohler S, et al. CD30+ cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49:1049–1058
  8. Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Characterization of clinical subset with worse outcome. Arch Dermatol. 2009;145:667–674
  9. Kodama K, Fink-Puches R, Massone C, et al. Papular mycosis fungoides: A new clinical variant of early mycosis fungoides. J Am Acad Dermatol. 2005;52:694–698
  10. El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulosis: Reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol. 2004;140:441–447
  11. Kummer JA, Vermeer MH, Dukers D, et al. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol. 1997;109:636–640
  12. de Souza A, Camilleri MJ, Wada DA, et al. Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J Am Acad Dermatol. 2009;Epub ahead of print
  13. Sioutos N, Asvesti C, Sivridis E, et al. Lymphomatoid papulosis type A: Clinical, morphologic, and immunophenotypic study. Int J Dermatol. 1997;36:514–517
  14. Benner MF, Jansen PM, Meijer CJ, Willemze R. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol. 2009;161:121–127
  15. Flann S, Orchard GE, Wain EM, Russell-Jones R. Three cases of lymphomatoid papulosis with a CD56+ immunophenotype. J Am Acad Dermatol. 2006;55:903–906
  16. Scarisbrick JJ, Calonje E, Orchard G, et al. Pseudocarcinomatous change in lymphomatoid papulosis and primary cutaneous CD30+ lymphoma: A clinicopathologic and immunohistochemical study of 6 patients. J Am Acad Dermatol. 2001;44:239–247
  17. Kempf W, Levi E, Kamarashev J, et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol. 2002;29:295–300
  18. Gniadecki R, Rossen K. Expression of T-cell activation marker CD134 (OX40) in lymphomatoid papulosis. Br J Dermatol. 2003;148:885–891
  19. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed–Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848–858
  20. Boudova L, Kazakov DV, Jindra P, et al. Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman. J Cutan Pathol. 2006;33:584–589
  21. Herbst H, Sander C, Tronnier M, et al. Absence of anaplastic lymphoma kinase (ALK) and Epstein–Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis. Br J Dermatol. 1997;137:680–686
  22. Lae ME, Ahmed I, Macon WR. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol. 2002;118:773–779
  23. Rassidakis GZ, Georgakis GV, Oyarzo M, et al. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol. 2004;17:946–953
  24. Kempf W, Kutzner H, Cozzio A, et al. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: A valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol. 2008;158:1280–1287
  25. Kempf W, Kadin ME, Dvorak AM, et al. Endogenous retroviral elements, but not exogenous retroviruses, are detected in CD30-positive lymphoproliferative disorders of the skin. Carcinogenesis. 2003;24:301–306
  26. Dreno B, Milpied-Homsi B, Moreau P, et al. Cutaneous anaplastic T-cell lymphoma in a patient with human immunodeficiency virus infection: Detection of Epstein–Barr virus DNA. Br J Dermatol. 1993;129:77–81
  27. Lucioni M, Ippoliti G, Campana C, et al. EBV positive primary cutaneous CD30+ large T-cell lymphoma in a heart transplanted patient: Case report. Am J Transplant. 2004;4:1915–1920
  28. Yamaguchi T, Ohshima K, Karube K, et al. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders. Br J Dermatol. 2006;154:904–909
  29. Greisser J, Doebbeling U, Roos M, et al. Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp Dermatol. 2005;14:380–385
  30. Mori M, Manuelli C, Pimpinelli N, et al. CD30–CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. Blood. 1999;94:3077–3083
  31. Paulli M, Berti E, Boveri E, et al. Cutaneous CD30+ lymphoproliferative disorders: Expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol. 1998;29:1223–1230
  32. Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations. Eur J Haematol. 2008;80:483–489
  33. Kadin ME. Pathobiology of CD30+ cutaneous T-cell lymphomas. J Cutan Pathol. 2006;33(suppl 1):10–17
  34. Gellrich S, Wernicke M, Wilks A, et al. The cell infiltrate in lymphomatoid papulosis comprises a mixture of polyclonal large atypical cells (CD30-positive) and smaller monoclonal T cells (CD30-negative). J Invest Dermatol. 2004;122:859–861
  35. Steinhoff M, Hummel M, Anagnostopoulos I, et al. Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. Blood. 2002;100:578–584
  36. Gniadecki R. Neoplastic stem cells in cutaneous lymphomas: Evidence and clinical implications. Arch Dermatol. 2004;140:1156–1160
  37. Gniadecki R, Lukowsky A, Rossen K, et al. Bone marrow precursor of extranodal T-cell lymphoma. Blood. 2003;102:3797–3799
  38. Smoller BR, Longacre TA, Warnke RA. Ki-1 (CD30) expression in differentiation of lymphomatoid papulosis from arthropod bite reactions. Mod Pathol. 1992;5:492–496
  39. Werner B, Massone C, Kerl H, Cerroni L. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol. 2008;35:1100–1107
  40. Herron MD, Bohnsack JF, Vanderhooft SL. Septic, CD-30 positive febrile ulceronecrotic pityriasis lichenoides et varioliformis acuta. Pediatr Dermatol. 2005;22:360–365
  41. Guitart J, Hurt MA. Pleomorphic T-cell infiltrate associated with molluscum contagiosum. Am J Dermatopathol. 1999;21:178–180
  42. Cepeda LT, Pieretti M, Chapman SF, Horenstein MG. CD30-positive atypical lymphoid cells in common non-neoplastic cutaneous infiltrates rich in neutrophils and eosinophils. Am J Surg Pathol. 2003;27:912–918
  43. Chai C, White WL, Shea CR, Prieto VG. Epstein Barr virus-associated lymphoproliferative-disorders primarily involving the skin. J Cutan Pathol. 1999;26:242–247
  44. Chiu LS, Choi PC, Luk NM, et al. Spontaneous regression of primary cutaneous Epstein–Barr virus-positive, CD30-positive anaplastic large T-cell lymphoma in a heart-transplant recipient. Clin Exp Dermatol. 2009;34:e21–e24
  45. Cesinaro AM, Maiorana A. Verruca vulgaris with CD30-positive lymphoid infiltrate: A case report. Am J Dermatopathol. 2002;24:260–263
  46. Fukamachi S, Sugita K, Sawada Y, et al. Drug-induced CD30+ T cell pseudolymphoma. Eur J Dermatol. 2009;19:292–294
  47. Nathan DL, Belsito DV. Carbamazepine-induced pseudolymphoma with CD-30 positive cells. J Am Acad Dermatol. 1998;38:806–809
  48. Evans AV, Sabroe RA, Liddell K, Russell-Jones R. Lymphocytic infiltrates as a presenting feature of Sweet's syndrome with myelodysplasia and response to cyclophosphamide. Br J Dermatol. 2002;146:1087–1090
  49. Vignon-Pennamen MD, Juillard C, Rybojad M, et al. Chronic recurrent lymphocytic Sweet's syndrome as a predictive marker of myelodysplasia: A report of 9 cases. Arch Dermatol. 2006;142:1170–1176
  50. Introcaso CE, Kantor J, Porter DL, Junkins-Hopkins JM. Cutaneous Hodgkin's disease. J Am Acad Dermatol. 2008;58:295–298

PII: S0740-2570(09)00020-3

doi: 10.1053/j.semdp.2009.09.001

Seminars in Diagnostic Pathology
Volume 26, Issue 3 , Pages 131-140 , August 2009

Article Tools

* Image Usage & Resolution